Global biopharmaceutical company UCB has launched Wellness 4U, an insights-driven health and wellness program designed to inspire positive behavior change, increase commitment to wellness and help improve the overall well-being of people living with immunologic disorders who have high unmet needs.
Wellness 4U is a multi-channel health and wellness program that utilizes several initiatives aimed to elevate patient outcomes beyond therapeutic support. Key programs include a Wellness 4U Activity Tracker, a health outcomes research collaboration with the IBD Support Foundation, a national wellness education panel speaker event series addressing the entire care team and a nurse practitioner/physician's assistant educational initiative.
The first component, the Wellness 4U Activity Tracker pilot program, works with physicians to provide CIMZIA (certolizumab pegol)-treated patients living with moderate-to-severe rheumatoid arthritis (RA) a Garmin vivofit 2 activity tracker to monitor their daily steps and sleep patterns. Patients enrolled in the program can access the Wellness 4U online community platform that offers tracking capabilities for data sourced from their activity trackers and other healthy lifestyle tips and information to aid in improving overall wellness and physical health. Insights gathered through the Activity Tracker program should help enable healthcare professionals (HCPs) and patients to assess whether behavioral changes have impacted participant health.
"We are proud that we've been able to create Wellness 4U to equip patients and their healthcare team with tools to address mental, physical and social unmet needs," Todd Edwards, Vice President and Head of US Immunology at UCB, said in a statement. "This overarching Wellness 4U platform and the unique relationships it is forging are representative of the larger UCB commitment to being a trusted collaborator, actively pioneering in subpopulations with remaining unmet patient and provider needs."
The Wellness 4U Activity Tracker program has commenced in four U.S. cities — Houston, Texas; Charlotte, North Carolina; Louisville, Kentucky; and Los Angeles, California — with approximately 50 patients enrolled to-date.